Co-expression of IL-18 binding protein and IL-4 regulates Th1/Th2 cytokine response in murine collagen-induced arthritis

Acta Biochimica et Biophysica Sinica

Volumn 40, Issue 2, 2008, Pages 116-124

  Leng, Jianhang ^a   Yao, Hangping ^b   Shen, Junya ^a   Wang, Keyi ^a   Zhuo, Guangchao ^a   Wang, Ziwei ^a  

^a HANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Gene therapy; Interleukin 18 binding protein; Interleukin 4; Rheumatoid arthritis

Indexed keywords

ADENOVIRIDAE; MURINAE; MUS;

EID: 39749170765     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1111/j.1745-7270.2008.00384.x     Document Type: Article

References (38)

1. 1 Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996, 383: 787–793.
2. 2 Rapoport MJ, Jaramillo A, Zipris D, Lazarus AH, Serreze DV, Leiter EH, Cvopick P et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J Exp Med 1993, 178: 87–99.
3. 3 Mauri C, Williams RO, Walmsley M, Feldmann M. Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen‐induced arthritis. Eur J Immunol 1996, 26: 1511–1518.
4. 4 Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, Van Den Berg WB. Role of interleukin‐4 and interleukin‐10 in murine collagen‐induced arthritis. Protective effect of interleukin‐4 and interleukin‐10 treatment on cartilage destruction. Arthritis Rheum 1997, 40: 249–260.
5. 5 Brown MA, Hural J. Functions of IL‐4 and control of its expression. Crit Rev Immunol 1997, 17: 1–32.
6. 6 Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989, 170: 2081–2095.
7. 7 Ushio S, Namba M, Okura T, Hattori K, Nukada Y, Akita K, Tanabe F et al. Cloning of the cDNA for human IFN‐gamma‐inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. J Immunol 1996, 156: 4274–4279.
8. 8 Kohno K, Kurimoto M. Interleukin 18, a cytokine which resembles IL‐1 structurally and IL‐12 functionally but exerts its effect independently of both. Clin Immunol Immunopathol 1998, 86: 11–15.
9. 9 Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin‐18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999, 10: 127–136.
10. 10 Kamradt T, Burmester G‐R. Cytokines and arthritis: is the Th1/Th2 paradigm useful for understanding pathogenesis J Rheumatol 1998, 25: 6–8.
11. 11 Dolhain RJ, Van Der Heiden AN, Ter Haar NT, Breedveld FC, Miltenburg AM. Shift toward T lymphocytes with a T helper 1 cytokine‐secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996, 39: 1961–1969.
12. 12 Miossec P. Acting on the cytokine balance to control auto‐immunity and chronic inflammation. Eur Cytokine Netw 1993, 4: 245–251.
13. 13 Evans CH, Robbins PD. Progress toward the treatment of arthritis by gene therapy. Ann Med 1995, 27: 543–546.
14. 14 Bandara G, Robbins PD, Georgescu HI, Mueller GM, Glorioso JC, Evans CH. Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol 1992, 11: 227–231.
15. 15 Chernajovsky Y, Feldmann M, Maini RN. Gene therapy of rheumatoid arthritis via cytokine regulation: future perspectives. Br Med Bull 1995, 51: 503–561.
16. 16 Xing Z, Ohkawara Y, Jordana M, Graham F, Gauldie J. Transfer of granulocyte‐macrophage colony‐stimulating factor gene to rat lung induces eosinophilia, monocytosis and fibrotic reactions. J Clin Invest 1996, 97: 1102–1110.
17. 17 Yao HP, Zhou JY, Li D, Bader A, Stefan H, Wu NP, Brockmeyer NH. FK506 enhances triptolide‐induced cyclooxygenase‐2, inducible nitric oxide synthase and their inducing products PGE2, NO down‐regulation in human rheumatoid arthritis synovial fibroblasts. Eur J Med Res 2008, forthcoming.
18. 18 Miller EJ, Rhodes RK. Preparation and characterization of the different types of collagen. Methods Enzymol 1982, 2: 33–64.
19. 19 Joosten LA, Helsen MM, Van De Loo FA, Van Den Berg WB. Anticytokine treatment of established collagen type II arthritis in DBA/1 mice. A comparative study using anti‐TNF alpha, anti‐IL‐1 alpha/beta and IL‐1Ra. Arthritis Rheum 1996, 39: 797–809.
20. 20 Van De Loo FA, Smeets RL, Van Den Berg WB. Gene therapy in animal models of rheumatoid arthritis: are we ready for the patients Arthritis Res Ther 2004, 6: 183–196.
21. 21 Vervoordeldonk MJ, Tak PP. Cytokines in rheumatoid arthritis. Curr Rheumatol Rep 2002, 4: 208–217.
22. 22 Wahid S, Blades MC, De Lord D, Brown I, Blake G, Haskard DO, Panavi GS et al. Tumour necrosis factor‐alpha (TNF‐alpha) enhances lymphocyte migration into rheumatoid synovial tissue transplanted into severe combined immunodeficient (SCID) mice. Clin Exp Immunol 2000, 122: 133–142.
23. 23 Feldmann M. Development of anti‐TNF therapy for rheumatoid arthritis. Nat Rev Immunol 2002, 2: 364–371.
24. 24 Van Holten J, Reedquist K, Sattonet‐Roche P, Smeets TJ, Plater‐Zvberk C, Vervoordeldonk MJ, Tak PP. Treatment with recombinant interferon‐beta reduces inflammation and slows cartilage destruction in the collagen‐induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004, 6: R239–R249.
25. 25 Lubberts E, Joosten LA, Chabaud M, Van Den Bersselaar L, Oppers B, Coenen‐De Roo CJ, Richards CD et al. IL‐4 gene therapy for collagen arthritis suppresses synovial IL‐17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000, 105: 1697–1710.
26. 26 Te Velde AA, Huijbens RJ, Heije K, De Vries JE, Fiqdor CG. Interleukin‐4 (IL‐4) inhibits secretion of IL‐1 beta, tumor necrosis factor alpha, and IL‐6 by human monocytes. Blood 1990, 76: 1392–1397.
27. 27 Van Den Berg WB. Anti‐cytokine therapy in chronic destructive arthritis. Arthritis Res 2001, 3: 18–26.
28. 28 Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, Arend WP. Synovial interleukin‐1 receptor antagonist and interleukin‐1 balance in rheumatoid arthritis. Arthritis Rheum 1994, 37: 644–652.
29. 29 Wong HL, Costa GL, Lotze MT, Wahl SM. Interleukin (IL) 4 differentially regulates monocyte IL‐1 family gene expression and synthesis in vitro and in vivo. J Exp Med 1993, 177: 775–781.
30. 30 Haas CS, Amin MA, Allen BB, Ruth JH, Haines GK 3rd, Woods JM, Koch AE. Inhibition of angiogenesis by interleukin‐4 gene therapy in rat adjuvant‐induced arthritis. Arthritis Rheum 2006, 54: 2402–2414.
31. 31 Dinarello CA. Interleukin‐18. Methods 1999, 19: 121–132.
32. 32 Yamamura M, Kawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, Morita Y et al. Interferon‐gamma‐inducing activity of interleukin‐18 in the joint with rheumatoid arthritis. Arthritis Rheum 2001, 44: 275–285.
33. 33 Leung BP, McInnes IB, Esfandiari E, Wei XQ, Liew FY. Combined effects of IL‐12 and IL‐18 on the induction of collagen‐induced arthritis. J Immunol 2000, 164: 6495–6502.
34. 34 Joosten LA, Smeets RL, Koenders MI, Van Den Bersselaar LA, Helsen MM, Oppers‐Walgreen B, Lubberts E et al. Interleukin‐18 promotes joint inflammation and induces interleukin‐1‐driven cartilage destruction. Am J Pathol 2004, 165: 959–967.
35. 35 Wei XQ, Leung BP, Arthur HM, McInnes IB, Liew FY. Reduced incidence and severity of collagen‐induced arthritis in mice lacking IL‐18. J Immunol 2001, 166: 517–521.
36. 36 Kim SH, Eisenstein M, Reznikov L, Fantuzzi G, Novick D, Rubinstein M, Dinarello CA. Structural requirements of six naturally occurring isoforms of the IL‐18 binding protein to inhibit IL‐18. Proc Natl Acad Sci USA 2000, 97: 1190–1195.
37. 37 Smeets RL, Van De Loo FA, Arntz OJ, Bennink MB, Joosten LA, Van Den Berg WB. Adenoviral delivery of IL‐18 binding protein C ameliorates collagen‐induced arthritis in mice. Gene Ther 2003, 10: 1004–1011.
38. 38 Yin Z, Siegert S, Neure L, Grolms M, Liu L, Eqqens U, Radbruch A et al. The elevated ratio of interferon gamma‐/interleukin‐4‐positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin‐4 but not by interleukin‐10 or transforming growth factor beta. Rheumatology (Oxford) 1999, 38: 1058–1067.